TFAP2B

TFAP2B Full Name

transcription factor AP-2 beta (activating enhancer binding protein 2 beta)

TFAP2B Introduction

TFAP2B (also known as AP-2 beta) is a member of the activating protein-2 (AP-2) family of transcription factors, which includes AP-2 alpha, beta, gamma, delta, and epsilon. Like other family members, TFAP2B contains a highly conserved C-terminal basic helix-span-helix dimerization domain that mediates homodimerization or heterodimerization with other AP-2 proteins and enables sequence-specific DNA binding to the core consensus motif 5'-GCCNNNGGC-3'. The N-terminal proline-rich and glutamine-rich region functions as a transactivation domain that recruits co-activators such as p300 and CBP to initiate transcription of target genes. TFAP2B is essential for normal development, particularly of the neural crest, kidney, and limbs, as demonstrated by the severe congenital abnormalities observed in humans with TFAP2B mutations. Unlike the broadly expressed TFAP2A, TFAP2B exhibits a more restricted expression pattern, with highest levels in the brain, heart, kidney, and adipose tissue. Mutations in TFAP2B cause Char syndrome, an autosomal dominant disorder characterized by patent ductus arteriosus (PDA), facial dysmorphism, and hand anomalies, underscoring its critical role in cardiovascular and craniofacial development.

Figure 1. Schematic structure of TFAP2B.

Biological Functions in Embryonic Development and Adipogenesis
TFAP2B plays essential roles in multiple developmental processes, particularly in neural crest-derived tissues, the cardiovascular system, and adipose tissue. During embryogenesis, TFAP2B is expressed in the neural crest, developing heart (particularly the cardiac neural crest and outflow tract), kidney, limbs, and cranial ganglia. In the cardiovascular system, TFAP2B regulates the development and remodeling of the ductus arteriosus, a fetal blood vessel that connects the pulmonary artery to the aorta and normally closes shortly after birth. TFAP2B controls the expression of genes involved in smooth muscle cell proliferation, differentiation, and contraction, including EPAS1 (HIF-2 alpha) and thromboxane A2 receptor, which are essential for ductus arteriosus closure. In the kidney, TFAP2B regulates nephron development and ureteric bud branching. In adipose tissue, TFAP2B is a key regulator of adipocyte differentiation (adipogenesis) and lipid metabolism. It controls the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), C/EBP alpha, and other adipogenic transcription factors, and also regulates leptin expression and insulin sensitivity. TFAP2B knockout mice die perinatally with severe cardiovascular defects including persistent truncus arteriosus and interrupted aortic arch, as well as craniofacial and kidney abnormalities, phenotypes that partially overlap with but are distinct from Tfap2a knockout mice.

Clinical Significance: Char Syndrome and Other Disorders
Heterozygous loss-of-function mutations in TFAP2B cause Char syndrome (OMIM #169100), an autosomal dominant disorder characterized by the triad of patent ductus arteriosus (PDA), facial dysmorphism, and hand anomalies. PDA results from failure of the ductus arteriosus to close after birth, leading to abnormal blood flow between the aorta and pulmonary artery. The facial features of Char syndrome include a flat nasal bridge, broad nasal tip, widely spaced eyes (hypertelorism), low-set and posteriorly rotated ears, a long philtrum, and a thin upper lip. Hand anomalies include short fingers (brachydactyly), tapered fingers, clinodactyly (curved fifth finger), and abnormal palmar creases. Additional features may include hearing loss, dental anomalies, and cognitive or behavioral issues in some patients. Over 30 different TFAP2B mutations have been identified in Char syndrome, including missense, nonsense, frameshift, and splice-site mutations, as well as whole-gene deletions. Most mutations cluster in the basic helix-span-helix domain, disrupting DNA binding and dimerization, consistent with a dominant-negative mechanism. Interestingly, some TFAP2B mutations have been identified in isolated PDA without other features of Char syndrome, suggesting that TFAP2B testing should be considered in familial and sporadic PDA cases. Beyond Char syndrome, TFAP2B polymorphisms have been associated with obesity, type 2 diabetes, and hypertension, reflecting its role in adipogenesis and metabolic regulation.

Alternate Names for TFAP2B

TFAP2B; transcription factor AP-2 beta (activating enhancer binding protein 2 beta); AP-2B; AP2-B; transcription factor AP-2-beta; AP2-beta; activating enhancer binding protein 2 beta; activating enhancer-binding protein 2-beta;

View more